However, a retrospective analysis of metastatic UMs treated with one of the anti-VEGF antibodies, bevacizumab, compared to the group not receiving this antibody, showed no statistical difference [90]. The gene discussed is VEGFA; the disease is ulnar-mammary syndrome.